Diabetes-related cardiomyopathy: The sweet story of glucose overload from epidemiology to cellular pathways

Diabetes and Metabolism

Volumn 45, Issue 3, 2019, Pages 238-247

  Joubert, M ^a,b   Manrique, A ^a,b   Cariou, B ^c   Prieur, X ^c  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b France   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

Diabetic cardiomyopathy; Glucotoxicity; Hexosamine pathway; Oral hypoglycaemic agents; SGLT2 inhibitors; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIDIABETIC AGENT; GLUCOSE; HEXOSAMINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

BIOSYNTHESIS; CARDIAC IMAGING; CLINICAL ASSESSMENT; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHENOTYPE; PRECLINICAL STUDY; PREVALENCE; REVIEW; SIGNAL TRANSDUCTION; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; RISK FACTOR;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; HUMANS; HYPERGLYCEMIA; OXIDATIVE STRESS; PREVALENCE; RISK FACTORS;

EID: 85050849951     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2018.07.003     Document Type: Review

References (133)

1. NCD Risk Factor Collaboration (NCD-RisC), Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387 (2016), 1513–1530.
2. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration, Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol 2 (2014), 634–647.
3. Gregg, E.W., Gu, Q., Cheng, Y.J., Narayan, K.M., Cowie, C.C., Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 147 (2007), 149–155.
4. Franjic, B., Marwick, T.H., The diabetic, hypertensive heart: epidemiology and mechanisms of a very high-risk situation. J Hum Hypertens 23 (2009), 709–717.
5. Nichols, G.A., Gullion, C.M., Koro, C.E., Ephross, S.A., Brown, J.B., The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27 (2004), 1879–1884.
6. Norhammar, A., Bodegård, J., Nyström, T., Thuresson, M., Eriksson, J.W., Nathanson, D., Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006–2013. Diabetologia 59 (2016), 1692–1701.
7. Clark, A.L., Cherif, M., McDonagh, T.A., Squire, I.B., In-hospital worsening heart failure: a clinically relevant endpoint?. ESC Heart Fail 5 (2018), 9–18.
8. Nichols, G.A., Hillier, T.A., Erbey, J.R., Brown, J.B., Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 24 (2001), 1614–1619.
9. Low Wang, C.C., Hess, C.N., Hiatt, W.R., Goldfine, A.B., Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus — Mechanisms, management, and clinical considerations. Circulation 133 (2016), 2459–2502.
10. Rubler, S., Dlugash, J., Yuceoglu, Y.Z., Kumral, T., Branwood, A.W., Grishman, A., New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30 (1972), 595–602.
11. Regan, T.J., Lyons, M.M., Ahmed, S.S., Levinson, G.E., Oldewurtel, H.A., Ahmad, M.R., et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 60 (1977), 884–899.
12. van Hoeven, K.H., Factor, S.M., A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 82 (1990), 848–855.
13. Goldin, A., Beckman, J.A., Schmidt, A.M., Creager, M.A., Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114 (2006), 597–605.
14. Factor, S.M., Minase, T., Sonnenblick, E.H., Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. Am Heart J 99 (1980), 446–458.
15. Fischer, V.W., Barner, H.B., Larose, L.S., Pathomorphologic aspects of muscular tissue in diabetes mellitus. Hum Pathol 15 (1984), 1127–1136.
16. Seferović, P.M., Paulus, W.J., Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 36 (2015), 1718–1727 [1727a–c].
17. Paulus, W.J., Tschöpe, C., Sanderson, J.E., Rusconi, C., Flachskampf, F.A., Rademakers, F.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28 (2007), 2539–2550.
18. Gonzalez, J.A., Kramer, C.M., Role of imaging techniques for diagnosis, prognosis and management of heart failure patients: cardiac magnetic resonance. Curr Heart Fail Rep 12 (2015), 276–283.
19. Khan, J.N., Wilmot, E.G., Leggate, M., Singh, A., Yates, T., Nimmo, M., et al. Subclinical diastolic dysfunction in young adults with Type 2 diabetes mellitus: a multiparametric contrast-enhanced cardiovascular magnetic resonance pilot study assessing potential mechanisms. Eur Heart J Cardiovasc Imaging 15 (2014), 1263–1269.
20. Redfield, M.M., Jacobsen, S.J., Burnett, J.C., Mahoney, D.W., Bailey, K.R., Rodeheffer, R.J., Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289 (2003), 194–202.
21. Doehner, W., Rauchhaus, M., Ponikowski, P., Godsland, I.F., von Haehling, S., Okonko, D.O., et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 46 (2005), 1019–1026.
22. Dauriz, M., Targher, G., Laroche, C., Temporelli, P.L., Ferrari, R., Anker, S., et al. ESC-HFA heart failure long-term registry, association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA heart failure long-term registry. Diabetes Care 40 (2017), 671–678.
23. Zhang, L., Liebelt, J.J., Madan, N., Shan, J., Taub, C.C., Comparison of predictors of heart failure ith preserved versus reduced ejection fraction in a multiracial cohort of preclinical left ventricular diastolic dysfunction. Am J Cardiol 119 (2017), 1815–1820.
24. Itzhaki Ben Zadok, O., Kornowski, R., Goldenberg, I., Klempfner, R., Toledano, Y., Biton, Y., et al. Admission blood glucose and 10-year mortality among patients with or without pre-existing diabetes mellitus hospitalized with heart failure. Cardiovasc Diabetol, 16, 2017, 102.
25. Bertoni, A.G., Hundley, W.G., Massing, M.W., Bonds, D.E., Burke, G.L., Goff, D.C., Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27 (2004), 699–703.
26. MacDonald, M.R., Petrie, M.C., Varyani, F., Ostergren, J., Michelson, E.L., Young, J.B., et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: assessment of reduction in mortality and morbidity (CHARM)programme. Eur Heart J 29 (2008), 1377–1385.
27. Holland, D.J., Marwick, T.H., Haluska, B.A., Leano, R., Hordern, M.D., Hare, J.L., et al. Subclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus. Heart 101 (2015), 1061–1066.
28. Iribarren, C., Karter, A.J., Go, A.S., Ferrara, A., Liu, J.Y., Sidney, S., et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 103 (2001), 2668–2673.
29. Erqou, S., Lee, C.T., Suffoletto, M., Echouffo-Tcheugui, J.B., de Boer, R.A., van Melle, J.P., et al. Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta-analysis. Eur J Heart Fail 15 (2013), 185–193.
30. Kristensen, S.L., Jhund, P.S., Mogensen, U.M., Rørth, R., Abraham, W.T., Desai, A., et al. Prognostic value of N-terminal Pro-B-type natriuretic peptide levels in heart failure patients with and without atrial fibrillation. Circ Heart Fail, 10, 2017 [pii: e004409].
31. Gerstein, H.C., Miller, M.E., Byington, R.P., Goff, D.C., Bigger, J.T., Buse, J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
32. Aguilar, H., Fricovsky, E., Ihm, S., Schimke, M., Maya-RamosL, Aroonsakool, N., et al. Role for high-glucose-induced protein O-GlcNAcylation in stimulating cardiac fibroblast collagen synthesis. Am J Physiol Cell Physiol 306 (2014), C794–C804.
33. 1c and mortality in diabetic individuals with heart failure: a population cohort study. Eur J Heart Fail 18 (2016), 94–102.
34. Guy, J., Ogden, L., Wadwa, R.P., Hamman, R.F., Mayer-Davis, E.J., Liese, A.D., et al. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for diabetes in youth case-control study. Diabetes Care 32 (2009), 416–420.
35. Cusi, K., Sanyal, A.J., Zhang, S., Hartman, M.L., Bue-Valleskey, J.M., Hoogwerf, B.J., et al. Non-alcoholic fatty liver disease (NAFLD)prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab 19 (2017), 1630–1634.
36. Ritchie, R.H., Zerenturk, E.J., Prakoso, D., Calkin, A.C., Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy. J Mol Endocrinol 58 (2017), R225–R240.
37. Rosengren, A., Vestberg, D., Svensson, A.M., Kosiborod, M., Clements, M., Rawshani, A., et al. Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study. Lancet Diabetes Endocrinol 3 (2015), 876–885.
38. Raev, D.C., Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type I diabetic patients. Diabetes Care 17 (1994), 633–639.
39. Berková, M., Opavský, J., Berka, Z., Skranka, V., Salinger, J., Left ventricular diastolic filling in young persons with type 1 diabetes mellitus. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 147 (2003), 57–61.
40. Labombarda, F., Leport, M., Morello, R., Ribault, V., Kauffman, D., Brouard, J., et al. Longitudinal left ventricular strain impairment in type 1 diabetes children and adolescents: a 2D speckle strain imaging study. Diabetes Metab 40 (2014), 292–298.
41. Fiorina, P., La Rocca, E., Astorri, E., Lucignani, G., Rossetti, C., Fazio, F., et al. Reversal of left ventricular diastolic dysfunction after kidney-pancreas transplantation in type 1 diabetic uremic patients. Diabetes Care 23 (2000), 1804–1810.
42. Wong, T.C., Piehler, K.M., Kang, I.A., Kadakkal, A., Kellman, P., Schwartzman, D.S., et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J 35 (2014), 657–664.
43. Grothues, F., Smith, G.C., Moon, J.C., Bellenger, N.G., Collins, P., Klein, H.U., et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90 (2002), 29–34.
44. Joubert, M., Tager, P., Legallois, D., Defourneaux, E., Le Guellec, B., Gerber, B., et al. Test-retest reproducibility of cardiac magnetic resonance imaging in healthy mice at 7-Tesla: effect of anesthetic procedures. Sci Rep, 7, 2017, 6698.
45. Cao, Y., Zeng, W., Cui, Y., Kong, X., Wang, M., Yu, J., et al. Increased myocardial extracellular volume assessed by cardiovascular magnetic resonance T1 mapping and its determinants in type 2 diabetes mellitus patients with normal myocardial systolic strain. Cardiovasc Diabetol, 17, 2018, 7.
46. Poirier, P., Bogaty, P., Garneau, C., Marois, L., Dumesnil, J.G., Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of manoeuvres in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24 (2001), 5–10.
47. Boyer, J.K., Thanigaraj, S., Schechtman, K.B., Pérez, J.E., Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 93 (2004), 870–875.
48. Ernande, L., Audureau, E., Jellis, C.L., Bergerot, C., Henegar, C., Sawaki, D., et al. Clinical implications of echocardiographic phenotypes of patients with diabetes mellitus. J Am Coll Cardiol 70 (2017), 1704–1716.
49. Ernande, L., Bergerot, C., Girerd, N., Thibault, H., Davidsen, E.S., Gautier Pignon-Blanc, P., et al. Longitudinal myocardial strain alteration is associated with left ventricular remodeling in asymptomatic patients with type 2 diabetes mellitus. J Am Soc Echocardiogr 27 (2014), 479–488.
50. Liu, J.H., Chen, Y., Yuen, M., Zhen, Z., Chan, C.W., Lam, K.S.H., et al. Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus. Cardiovasc Diabetol, 15, 2016, 22.
51. 1c identifies subjects with prediabetes and subclinical left ventricular diastolic dysfunction. J Clin Endocrinol Metab 102 (2017), 3756–3764.
52. Leung, M., Wong, V.W., Hudson, M., Leung, D.Y., Impact of improved glycemic control on cardiac function in type 2 diabetes mellitus. Circ Cardiovasc Imaging, 9, 2016, e003643.
53. Rijzewijk, L.J., van der Meer, R.W., Lamb, H.J., de Jong, H.W., Lubberink, M., Romijn, J.A., et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 54 (2009), 1524–1532.
54. Pascual, F., Coleman, R.A., Fuel availability and fate in cardiac metabolism: a tale of two substrates. Biochim Biophys Acta 1861 (2016), 1425–1433.
55. Bertrand, L., Horman, S., Beauloye, C., Vanoverschelde, J.L., Insulin signalling in the heart. Cardiovasc Res 79 (2008), 238–248.
56. Mazumder, P.K., O'Neill, B.T., Roberts, M.W., Buchanan, J., Yun, U.J., Cooksey, R.C., et al. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 53 (2004), 2366–2374.
57. Taegtmeyer, H., McNulty, P., Young, M.E., Adaptation and maladaptation of the heart in diabetes: part I: general concepts. Circulation 105 (2002), 1727–1733.
58. Young, M.E., McNulty, P., Taegtmeyer, H., Adaptation and maladaptation of the heart in diabetes: part II: potential mechanisms. Circulation 105 (2002), 1861–1870.
59. Rodrigues, B., Cam, M.C., McNeill, J.H., Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol 27 (1995), 169–179.
60. Bugger, H., Boudina, S., Hu, X.X., Tuinei, J., Zaha, V.G., Theobald, H.A., et al. Type 1 diabetic akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3. Diabetes 57 (2008), 2924–2932.
61. Hafstad, A.D., Solevåg, G.H., Severson, D.L., Larsen, T.S., Aasum, E., Perfused hearts from Type 2 diabetic (db/db)mice show metabolic responsiveness to insulin. Am J Physiol Heart Circ Physiol 290 (2006), H1763–H1769.
62. Shoghi, K.I., Gropler, R.J., Sharp, T., Herrero, P., Fettig, N., Su, Y., et al. Time course of alterations in myocardial glucose utilization in the Zucker diabetic fatty rat with correlation to gene expression of glucose transporters: a small-animal PET investigation. J Nucl Med 49 (2008), 1320–1327.
63. Welch, M.J., Lewis, J.S., Kim, J., Sharp, T.L., Dence, C.S., Gropler, R.J., et al. Assessment of myocardial metabolism in diabetic rats using small-animal PET: a feasibility study. J Nucl Med 47 (2006), 689–697.
64. van den Brom, C.E., Huisman, M.C., Vlasblom, R., Boontje, N.M., Duijst, S., Lubberink, M., et al. Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography. Cardiovasc Diabetol, 8, 2009, 39.
65. Ménard, S.L., Croteau, E., Sarrhini, O., Gélinas, R., Brassard, P., Ouellet, R., et al. Abnormal in vivo myocardial energy substrate uptake in diet-induced type 2 diabetic cardiomyopathy in rats. Am J Physiol Endocrinol Metab 298 (2010), E1049–E1057.
66. Gupte, A.A., Minze, L.J., Reyes, M., Ren, Y., Wang, W., Brunner, G., et al. High-fat feeding-induced hyperinsulinemia increases cardiac glucose uptake and mitochondrial function despite peripheral insulin resistance. Endocrinology 154 (2013), 2650–2662.
67. Joubert, M., Jagu, B., Montaigne, D., Marechal, X., Tesse, A., Ayer, A., et al. The SGLT2 Inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes 66 (2017), 1030–1040.
68. Thorn, S.L., de Kemp, R.A., Dumouchel, T., Klein, R., Renaud, J.M., Wells, R.G., et al. Repeatable non-invasive measurement of mouse myocardial glucose uptake with 18F-FDG: evaluation of tracer kinetics in a type 1 diabetes model. J Nucl Med 54 (2013), 1637–1644.
69. Kaneta, T., Hakamatsuka, T., Takanami, K., Yamada, T., Takase, K., Sato, A., et al. Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period, and hospitalization. Ann Nucl Med 20 (2006), 203–208.
70. Chatham, J.C., Seymour, A.M., Cardiac carbohydrate metabolism in Zucker diabetic fatty rats. Cardiovasc Res 55 (2002), 104–112.
71. Le Page, L.M., Rider, O.J., Lewis, A.J., Ball, V., Clarke, K., Johansson, E., et al. Increasing pyruvate dehydrogenase flux as a treatment for diabetic cardiomyopathy: a combined 13C hyperpolarized magnetic resonance and echocardiography study. Diabetes 64 (2015), 2735–2743.
72. Taegtmeyer, H., Beauloye, C., Harmancey, R., Hue, L., Insulin resistance protects the heart from fuel overload in dysregulated metabolic states. Am J Physiol Heart Circ Physiol 305 (2013), H1693–H1697.
73. Montaigne, D., Marechal, X., Coisne, A., Debry, N., Modine, T., Fayad, G., et al. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation 130 (2014), 554–564.
74. Joubert, M., Jagu, B., Montaigne, D., Marechal, X., Tesse, A., Ayer, A., et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes 66 (2017), 1030–1040.
75. Habibi, J., Aroor, A.R., Sowers, J.R., Jia, G., Hayden, M.R., Garro, M., et al. Sodium glucose transporter 2 (SGLT2)inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol, 16, 2017, 9.
76. Cai, L., Li, W., Wang, G., Guo, L., Jiang, Y., Kang, Y.J., Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 51 (2002), 1938–1948.
77. Sen, S., Kundu, B.K., Wu, H.C., Hashmi, S.S., Guthrie, P., Locke, L.W., et al. Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart. J Am Heart Assoc, 2, 2013, e004796.
78. Dyntar, D., Sergeev, P., Klisic, J., Ambühl, P., Schaub, M.C., Donath, M.Y., High glucose alters cardiomyocyte contacts and inhibits myofibrillar formation. J Clin Endocrinol Metab 91 (2006), 1961–1967.
79. Giacco, F., Brownlee, M., Oxidative stress and diabetic complications. Circ Res 107 (2010), 1058–1070.
80. Fiordaliso, F., Bianchi, R., Staszewsky, L., Cuccovillo, I., Doni, M., Laragione, T., et al. Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol 37 (2004), 959–968.
81. MacCarthy, P.A., Grieve, D.J., Li, L.M., Dunster, C., Kelly, F.J., Shah, M.A., Impaired endothelial regulation of ventricular relaxation in cardiac hypertrophy: role of reactive oxygen species and NADPH oxidase. Circulation 104 (2001), 2967–2974.
82. Bendall, J.K., Damy, T., Ratajczak, P., Loyer, X., Monceau, V., Marty, I., et al. Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in beta-adrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat. Circulation 110 (2004), 2368–2375.
83. Heymes, C., Bendall, J.K., Ratajczak, P., Cave, A.C., Samuel, J.L., Hasenfuss, G., et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 41 (2003), 2164–2171.
84. Kolwicz, S.C., Tian, R., Glucose metabolism and cardiac hypertrophy. Cardiovasc Res 90 (2011), 194–201.
85. 2+-ATPase and myosin heavy chain isozyme switch. Diabetologia 49 (2006), 1434–1446.
86. Serpillon, S., Floyd, B.C., Gupte, R.S., George, S., Kozicky, M., Neito, V., et al. Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. Am J Physiol Heart Circ Physiol 297 (2009), H153–H162.
87. Li, Y., Feng, Q., Arnold, M., Peng, T., Calpain activation contributes to hyperglycaemia-induced apoptosis in cardiomyocytes. Cardiovasc Res 84 (2009), 100–110.
88. Balteau, M., Tajeddine, N., de Meester, C., Ginion, A., des Rosiers, C., Brady, N.R., et al. NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc Res 92 (2011), 237–246.
89. Van Steenbergen, A., Balteau, M., Ginion, A., Ferté, L., Battault, S., Ravenstein, C.M., et al. Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart. Sci Rep, 8, 2017, 41166.
90. Shah, M.S., Brownlee, M., Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ Res 118 (2016), 1808–1829.
91. Ma, H., Li, S.Y., Xu, P., Babcock, S.A., Dolence, E.K., Brownlee, M., et al. Advanced glycation end-product (AGE)accumulation and AGE receptor (RAGE)up-regulation contribute to the onset of diabetic cardiomyopathy. J Cell Mol Med 13 (2009), 1751–1764.
92. Shao, C.H., Tian, C., Ouyang, S., Moore, C.J., Alomar, F., Nemet, I., et al. Carbonylation induces heterogeneity in cardiac ryanodine receptor function in diabetes mellitus. Mol Pharmacol 82 (2012), 383–399.
93. 2+ cycling defect in the diabetic heart. Heart Fail Rev 19 (2014), 101–112.
94. Clark, R.J., McDonough, P.M., Swanson, E., Trost, S.U., Suzuki, M., Fukuda, M., et al. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem 278 (2003), 44230–44237.
95. Hu, Y., Belke, D., Suarez, J., Swanson, E., Clark, R., Hoshijima, M., et al. Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart. Circ Res 96 (2005), 1006–1013.
96. Fricovsky, E.S., Suarez, J., Ihm, S.H., Scott, B.T., Suarez-Ramirez, J.A., Banerjee, I., et al. Excess protein O-GlcNAcylation and the progression of diabetic cardiomyopathy. Am J Physiol Regul Integr Comp Physiol 303 (2012), R689–R699.
97. Yokoe, S., Asahi, M., Takeda, T., Otsu, K., Taniguchi, N., Miyoshi, E., et al. Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathy. Glycobiology 20 (2010), 1217–1226.
98. Erickson, J.R., Pereira, L., Wang, L., Han, G., Ferguson, A., Dao, K., et al. Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature 502 (2013), 372–376.
99. 2+ sensitivity in diabetic cardiac muscle. Diabetes 64 (2015), 3573–3587.
100. Hu, Y., Suarez, J., Fricovsky, E., Wang, H., Scott, B.T., Trauger, S.A., et al. Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose. J Biol Chem 284 (2009), 547–555.
101. Banerjee, P.S., Ma, J., Hart, G.W., Diabetes-associated dysregulation of O-GlcNAcylation in rat cardiac mitochondria. Proc Natl Acad Sci U S A 112 (2015), 6050–6055.
102. Marsh, S.A., Dell'Italia, L.J., Chatham, J.C., Activation of the hexosamine biosynthesis pathway and protein O-GlcNAcylation modulate hypertrophic and cell signaling pathways in cardiomyocytes from diabetic mice. Amino Acids 40 (2011), 819–828.
103. Facundo, H.T., Brainard, R.E., Watson, L.J., Ngoh, G.A., Hamid, T., Prabhu, S.D., et al. GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol 302 (2012), H2122–H2130.
104. Stades, M.A., Heikens, J.T., Erkelens, D.W., Holleman, F., Hoekstra, J.B., Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med 255 (2004), 179–187.
105. Eurich, D.T., Weir, D.L., Majumdar, S.R., Tsuyuki, R.T., Johnson, J.A., Tjosvold, L., et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 6 (2013), 395–402.
106. Ruiter, R., Visser, L.E., van Herk-Sukel, M.P., Geelhoed-Duijvestijn, P.H., de Bie, S., Straus, S.M., et al. Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008. Drug Saf 35 (2012), 471–480.
107. Gilbert, R.E., Krum, H., Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 385 (2015), 2107–2117.
108. Komajda, M., McMurray, J.J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Pocock, S.J., et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 31 (2010), 824–831.
109. Young, L.H., Viscoli, C.M., Schwartz, G.G., Inzucchi, S.E., Curtis, J.P., Gorman, M.J., et al. Heart failure after ischemic stroke or TIA in insulin-resistant patients without diabetes treated with pioglitazone. Circulation, 2018 [Epub ahead of print].
110. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
111. Duckworth, D., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
112. Castagno, D., Baird-Gunning, J., Jhund, P.S., Biondi-Zoccai, G., MacDonald, M.R., Petrie, M.C., et al. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J, 162, 2011 [938–48e2].
113. Roussel, R., Steg, P.G., Mohammedi, K., Marre, M., Potier, L., Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: a perspective on glucose-lowering interventions. Diabetes Obes Metab 20 (2018), 238–244.
114. Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
115. White, W.B., Cannon, C.P., Heller, S.R., Nissen, S.E., Bergenstal, R.M., Bakris, G.L., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
116. Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
117. Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Køber, L.V., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
118. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
119. Holman, R.R., Bethel, M.A., Mentz, R.J., Thompson, V.P., Lokhnygina, Y., Buse, J.B., et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377 (2017), 1228–1239.
120. Gerstein, H.C., Bosch, J., Dagenais, G.R., Díaz, R., Jung, H., Maggioni, A.P., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367 (2012), 319–328.
121. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
122. Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
123. Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R.S., Nielsen, R., Hänselmann, A., et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—A multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19 (2017), 69–77.
124. Margulies, K.B., Hernandez, A.F., Redfield, M.M., Givertz, M.M., Oliveira, G.H., Cole, R., et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316 (2016), 500–508.
125. Anyanwagu, U., Mamza, J., Donnelly, R., Idris, I., Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: a large retrospective UK cohort study. Am Heart J 196 (2018), 18–27.
126. Kosiborod, M., Cavender, M.A., Fu, A.Z., Wilding, J.P., Khunti, K., Holl, R.W., et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation 136 (2017), 249–259.
127. Lytvyn, Y., Bjornstad, P., Udell, J.A., Lovshin, J.A., Cherney, D., Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 136 (2017), 1643–1658.
128. Inzucchi, S.E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41 (2018), 356–363.
129. Ferrannini, E., Mark, M., Mayoux, E., CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.
130. Lytvyn, Y., Škrtić, M., Yang, G.K., Yip, P.M., Perkins, B.A., Cherney, D.Z., Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 308 (2015), F77–F83.
131. Heerspink, H.J., Perkins, B.A., Fitchett, D.H., Husain, M., Cherney, D.Z., Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134 (2016), 752–772.
132. Martens, P., Mathieu, C., Verbrugge, F.H., Promise of SGLT2 inhibitors in heart failure: diabetes and beyond. Curr Treat Options Cardiovasc Med, 19, 2017, 23.
133. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.